Faeth Therapeutics
FTH
23 hedge funds and large institutions have $1.31M invested in Faeth Therapeutics in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 6 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0.04% less ownership
Funds ownership: 0.46% → 0.42% (-0.04%)
4% less funds holding
Funds holding: 24 → 23 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
46% less capital invested
Capital invested by funds: $2.43M → $1.31M (-$1.12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$676K |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$180K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$46.7K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$27.9K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$19.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
-$977K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$94.3K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$36.4K |
| 4 |
Millennium Management
New York
|
-$34.2K |
| 5 |
BlackRock
New York
|
-$26.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Two Sigma Advisers
New York
| – | -$19.9K | -950 | Closed |
|
27
Two Sigma Investments
New York
| – | -$10.7K | -509 | Closed |
|
28
UBS Group
Zurich,
Switzerland
| – | -$146 | -7 | Closed |
|
29
Wells Fargo
San Francisco,
California
| – | -$140 | -7 | Closed |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$187 | +9 | +300% |
|
FTH Hedge Fund Activity: Q2 2024 in Review
23 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q2 2024, worth a combined $1.31M — down 46% from $2.43M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of FTH and 5 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 6 added.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $676K. The largest seller was Newtyn Management, exiting entirely with an estimated $977K sold.
- 23 institutional investors held Faeth Therapeutics (FTH) as of Q2 2024, down from 24 in Q1 2024.
- Funds reported $1.31M of Faeth Therapeutics stock for Q2 2024, down 46% quarter-over-quarter.
- 5 funds opened new Faeth Therapeutics positions in Q2 2024 and 6 closed out, a net change of -1 holder.
- The largest Faeth Therapeutics buyer in Q2 2024 was Ikarian Capital, an estimated $676K added.
- The largest Faeth Therapeutics seller in Q2 2024 was Newtyn Management, an estimated $977K sold.
Based on aggregated 13F filings for Q2 2024.